Its a weekly weight-loss injection with semaglutide as the active ingredient
Brazil: Demand for GLP-1 companion products in Brazil is projected to grow at around an 11.8% CAGR through 2036, supported by expanding GLP-1 user base for obesity management and diabetes care, and growing demand for high-quality and convenient companion product formats such as sachets, bars, and liquid shots
These medications mimic hormones that tell your brain youre full, helping reduce calorie intake over time
Active research is assisting experts envision how these medications could benefit those living with obesity, diabetes, and associated conditions
Clinical trial data shows only 4.2% of participants discontinued due to side effects after week 24
For musculoskeletal injuries, subcutaneous injection near the injury site is generally preferred because it delivers the peptide directly to the damaged tissue